Supplementary Table

Supplementary Table 1 L-BLP25 Clinical Trials

Protocol number Population Start date Status	Description	Subjects		Treatment Schedule for L-BLP25 Vaccinations[a]			
		Enrolled	Treated with L-BLP25	Primary Treatment		Maintenance Treatment	
				Dose	Weeks	Dose	Interval[b]
NSCLC Trials							
EMR 63325-002 Stage IIIB or IV NSCLC 04 Aug 1998 Trial closed 17 Nov 2005	Phase I open-label safety & dose-comparison trial	17	16	20 or 200 µg	0,2,5,9	20 or 200 µg	Every 12 weeks
EMR 63325-003 Stage IIIB or IV NSCLC 06 Aug 1999 Trial closed 10 Dec 2004	Phase II open-label safety & immunogenicity trial	9	8	1000 µg	Weekly x 8	250 µg	Every 6 weeks
EMR 63325-004 Stage IIIB or IV NSCLC 24 Jan 2000 Trial closed 12 Dec 2005	Phase II open-label dose-escalation trial to determine safety & immunogenicity of L-BLP25 in combination with L-IL-2	18	18	1000 µg combined with 5×10^5 or 2×10^6 IU L-IL-2	Weekly x 8	250 µg	Every 6 weeks
EMR 63325-005 Stage IIIB or IV NSCLC 08 Aug 2000 Closed to enrollment	Phase IIb open-label randomized trial to test safety & efficacy of L-BLP25 plus best supportive care (BSC) compared to BSC alone	171	88	930 µg	Weekly x 8	930 µg	Every 6 weeks
EMR 63325-006 Unresected stage III NSCLC 18 Apr 2005 Closed to enrollment	Phase II open-label trial to assess safety of L-BLP25 made with immunoadjuvant MPL® from GSK Biologicals North America	22	22	930 µg	Weekly x 8	930 µg	Every 6 weeks
EMR 63325-001 Unresectable stage III NSCLC 22 Feb 2007 Open to enrollment	"START" trial. Phase III randomized, double-blind, placebo-controlled trial to test safety & efficacy of L-BLP25 plus BSC compared to BSC alone	1273[c]	Blinded	930 µg	Weekly x 8	930 µg	Every 6 weeks

Protocol number Population Start date Status	Description	Subjects		Treatment Schedule for L-BLP25 Vaccinations[a]			
		Enrolled	Treated with L-BLP25	Primary Treatment		Maintenance Treatment	
				Dose	Weeks	Dose	Interval[b]
EMR 63325-009 Unresectable stage III NSCLC 12 Feb 2009 (Step 1)	Combined phase I/ II trial of L-BLP25 in Japanese subjects with stage III unresectable NSCLC following primary chemo-radio-therapy	7	6	930 µg	Weekly x 8	930 µg	Every 6 weeks
EMR 63325-012 ("INSPIRE") Unresected stage III NSCLC 02 Dec 2009 Open to enrolment	Phase III randomized, double-blind, placebo-controlled trial to test safety &efficacy of L-BLP25 plus BSC compared to Placebo plus BSC in Asian patients	8[c]	Blinded	930 µg	Weekly x 8	930 µg	Every 6 weeks
Other Trials							
EMR 63325-007 Prostate cancer 26 Oct 2001 Trial closed 07 Jan 2005	Phase II open-label trial to test safety & efficacy of L-BLP25 in subjects with rising prostate-specific antigen values following radical prostatectomy	16	16	1000 µg	Weekly x 8	1000 µg	Every 6 weeks
EMR 63325-008 Multiple myeloma 21 Jan 2008 Open to enrollment	Phase II randomized, open-label trial to test safety & efficacy of L-BLP25 in combination with one or more administrations of cyclophosphamide[b]	34[c]	34[c]	930 µg	Weekly x 8	930 µg	Every 6 weeks

Protocol number Population Start date Status	Description	Subjects		Treatment Schedule for L-BLP25 Vaccinations[a]			
		Enrolled	Treated with L-BLP25	Primary Treatment		Maintenance Treatment	
				Dose	Weeks	Dose	Interval[b]
EMR 200038-010 ("STRIDE") Breast Cancer 20 Oct 2009 Trial terminated July 2010	Phase III randomized double-blind, placebo-controlled trial to test L-BLP25 in combination with hormonal treatment versus hormonal treatment alone for first-line therapy of post-menopausal women with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive, inoperable locally advanced, recurrent, or metastatic breast cancer	16[c]	Blinded	930 µg	Weekly x 8	930 µg	Every 6 weeks